A probiotic yeast-based immunotherapy against Clostridioides difficile infection.
A probiotic yeast-based immunotherapy against Clostridioides difficile infection.
复制标题
DOI:
10.1126/scitranslmed.aax4905
复制
发表时间:
2020-10-28
影响因子:
17.1
通讯作者:
Feng H
中科院分区:
文献类型:
--
作者:
Chen K;Zhu Y;Zhang Y;Hamza T;Yu H;Saint Fleur A;Galen J;Yang Z;Feng H
Antibiotic-resistant Clostridioides difficile is an anaerobic Gram-positive bacterium that colonizes the colon and is responsible for more than 29,000 deaths in the United States each year. Hence, C. difficile infection (CDI) poses an urgent threat to public health. Antibody-mediated neutralization of TcdA and TcdB toxins, the major virulence factors of CDI, represents an effective strategy to combat the disease without invoking antibiotic resistance. However, current antitoxin approaches are mostly based on parenteral infusion of monoclonal antibodies that are costly, narrow spectrum, and not optimized against the intestinal disease. Here, we engineered probiotic Saccharomyces boulardii to constitutively secrete a single tetra-specific antibody that potently and broadly neutralized both toxins and demonstrated protection against primary and recurrent CDI in both prophylactic and therapeutic mouse models of disease. This yeast immunotherapy is orally administered, can be used concurrently with antibiotics, and may have potential as a prophylactic against CDI risk and as a therapeutic for patients with CDI.
登录
查看更多内容
影响因子:
4.2
作者:
Chow SK;Casadevall A
通讯作者:
Casadevall A
影响因子:
14.8
作者:
Gietz, R. Daniel;Schiestl, Robert H.
通讯作者:
Schiestl, Robert H.
影响因子:
4.9
作者:
Douradinha, Bruno;Reis, Viviane C. B.;Marques, Ernesto T. A., Jr.
通讯作者:
Marques, Ernesto T. A., Jr.
影响因子:
--
作者:
Davies, Nicola L.;Compson, Joanne E.;Humphreys, David P.
通讯作者:
Humphreys, David P.
影响因子:
3.1
作者:
Castagliuolo, I;Riegler, MF;Pothoulakis, C
通讯作者:
Pothoulakis, C